Home » Newsletters » BioWorld Science

BioWorld Science

June 1, 1998

View Archived Issues

Fujisawa: FY 1998 highlights

Pentoxifylline shows efficacy in treatment of pruritus in HIV-infected patients

Compounds for bone diseases, neuropathy discovered at Takeda

New protein farnesyltransferase inhibitors prepared by Zeneca

Company Profile: ImmPheron

Imutech and Harvard Medical School join forces for clotrimazole development

Steroidogenesis Inhibitors seeks Romanian approval to begin pediatric trial with Anticort

Novartis and Trega sign agreement for obesity and diabetes research

Inex: Q1 1998 highlights

Schering AG presents factor Xa/thrombin inhibitors

Protein tyrosine or serine/threonine kinase inhibitors in development at Novartis

Agents for tumors and tumor metastasis synthesized at Ishihara Sangyo

Pfizer reports AChE inhibitors with memory-enhancing effects

Integrilin launched in first market today

New topical corticosteroid available in U.S. for ophthalmic use

Muscarinic receptor ligands from AHP with potential in treating cognition disorders

MMP/TNF-alpha convertase inhibitors disclosed by Agouron

JTV-519, a novel cardioprotective agent, and propranolol protect myocardium following SAH

FDA approves ADCON-L

ECG and hemodynamic evaluation of dronedarone, a new antiarrhythmic agent

Alzheimer's disease treatment launched in U.K.

Emisphere Technologies begins phase II trial with oral heparin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal
BioWorld
Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui...
Unique trial strategy muddies the ODAC waters for camizestrant
BioWorld
Following a discussion that focused more on a new personalized trial strategy rather than the proposed therapy, the U.S. FDA’s Oncologic Drugs Advisory Committee...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...